Stockscreener 앱 받기
1.06
3.64%
-0.04
시간 외 거래:
1.05
-0.01
-0.94%
Okyo Pharma Limited 주식(OKYO)의 최신 뉴스
OKYO Pharma Announces Chairman and CEO Acquire Shares -January 31, 2025 at 07:00 am EST - Marketscreener.com
OKYO Pharma insiders buy shares amid clinical trials - MSN
OKYO Pharma insiders acquire shares - Proactive Investors UK
OKYO Pharma insiders buy shares amid clinical trials By Investing.com - Investing.com South Africa
OKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believe - Proactive Investors USA
OKYO Pharma Executives Increase Shareholdings, Affirming Market Confidence - TipRanks
OKYO Pharma Announces Chairman and CEO Acquire Shares - The Manila Times
OKYO Pharma advances neuropathic corneal pain drug trial - MSN
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter - GlobeNewswire
OKYO Pharma Advances Clinical Trials with Encouraging Interim Results - TipRanks
OKYO Pharma nears full enrollment for neuropathic corneal pain trial with results expected by year-end - Proactive Investors UK
OKYO Pharma nears full enrollment for neuropathic corneal pain trial - Proactive Investors USA
OKYO Pharma secures $1.4 million in non-dilutive funding - MSN
OKYO Pharma secures $1.4 million non-dilutive funding - MSN
Okyo Pharma receives $1.4M in non-dilutive financing - Yahoo Finance
OKYO Pharma (NASDAQ:OKYO) Shares Down 0.4% – What’s Next? - Defense World
OKYO Pharma secures $1.4 million non-dilutive funding By Investing.com - Investing.com Australia
OKYO Pharma secures non-dilutive funding to advance clinical programs - Proactive Investors UK
OKYO Pharma receives $1.4 million in non-dilutive funding, stock up - MSN
OKYO Pharma Secures $1.4 Million to Boost Ophthalmic Innovations - TipRanks
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding - The Manila Times
OKYO Pharma secures $1.4 million in non-dilutive funding By Investing.com - Investing.com South Africa
OKYO Pharma Secures $1.4M Non-Dilutive Funding for Breakthrough Eye Pain Treatment - StockTitan
Neuropathic Ocular Pain Market Is Booming Worldwide 2025-2032 | - openPR
OKYO Pharma Limited ("OKYO" or the "Company")Conversion of CLNs, cashless exercise of Warrants, and issue of equity - Marketscreener.com
OKYO Pharma (NASDAQ:OKYO) & Adaptimmune Therapeutics (NASDAQ:ADAP) Head-To-Head Review - Defense World
OKYO Pharma (NASDAQ:OKYO) Stock Price Up 1.7% – Should You Buy? - Defense World
OKYO Pharma : Results of AGM 2024 - Marketscreener.com
Contrasting Genocea Biosciences (NASDAQ:GNCA) and OKYO Pharma (NASDAQ:OKYO) - Defense World
Critical Comparison: OKYO Pharma (NASDAQ:OKYO) versus enGene (NASDAQ:ENGN) - Defense World
OKYO Pharma (NASDAQ:OKYO) Trading Down 1% – What’s Next? - Defense World
OKYO Pharma to join BTIG Ophthalmology Day By Investing.com - Investing.com Canada
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference - GlobeNewswire
OKYO Pharma to join BTIG Ophthalmology Day - Investing.com
OKYO Pharma to Highlight Innovations at BTIG Conference - TipRanks
OKYO Pharma CEO to present at BTIG Ophthalmology Day - Proactive Investors USA
OKYO Pharma to Present at BTIG Ophthalmology Day, Showcases Neuropathic Pain Treatment | OKYO Stock News - StockTitan
Notice of AGM: December 2024 - Marketscreener.com
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
MUSQ ETF, OKYO Pharma CEOs Detail Growth Plans as Music Industry Targets $163B - StockTitan
OKYO Pharma (LON:OKYO) Trading Down 24.3% – Here’s What Happened - Defense World
OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference - Proactive Investors USA
3.95%
2.39%
자본화:
|
볼륨(24시간):